WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005115304) USE OF C-KIT INHIBITORS FOR TREATING FIBRODYSPLASIA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/115304    International Application No.:    PCT/IB2005/001371
Publication Date: 08.12.2005 International Filing Date: 19.04.2005
IPC:
A61K 31/426 (2006.01), A61K 31/421 (2006.01), A61K 31/506 (2006.01), A61P 19/08 (2006.01)
Applicants: AB SCIENCE [FR/FR]; 3, avenue George V, F-75008 Paris (FR) (For All Designated States Except US).
MOUSSY, Alain [FR/FR]; (FR) (For US Only).
KINET, Jean-Pierre [FR/US]; (US) (For US Only)
Inventors: MOUSSY, Alain; (FR).
KINET, Jean-Pierre; (US)
Agent: MARTIN, Jean-Jacques; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR)
Priority Data:
60/573,345 24.05.2004 US
Title (EN) USE OF C-KIT INHIBITORS FOR TREATING FIBRODYSPLASIA
(FR) UTILISATION D'INHIBITEURS DE C-KIT POUR LE TRAITEMENT DE LA FIBRODYSPLASIE
Abstract: front page image
(EN)The present invention relates to a method for treating fibrodysplasia such as fibrodysplasia ossificans progressive comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cell degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
(FR)L'invention concerne un procédé qui permet de traiter la fibrodysplasie telle que la fibrodysplasie ossifiante progressive, selon lequel on administre un composé capable de dépléter les mastocytes ou un composé inhibant la dégranulation des mastocytes à un humain qui en a besoin. Les composés tels que le composé précité peuvent être choisis parmi des inhibiteurs de c-kit et, en particulier, parmi des inhibiteurs de c-kit puissants, sélectifs et non toxiques. De préférence, l'inhibiteur n'est pas capable de promouvoir la mort des cellules dépendantes de l'IL-3 cultivées en présence d'IL-3.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)